|
|
Article: Mylan to retain Dey subsidiary.
- Article from:
- Pharma Marketletter
- Article date:
- September 15, 2008
CopyrightCOPYRIGHT 2008 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
USA-based generics giant Mylan says it will retain Dey LP, its branded specialty pharmaceutical subsidiary, following a comprehensive review of strategic alternatives.
The firm expects Dey will contribute positively to Mylan's earnings projections. Nonetheless, the company has reaffirmed its adjusted, diluted earnings per share guidance to: between $0.47 and $1.50, for 2008; from $0.53 to $1.10, in 2009; and $0.90 to $1.70, during 2010.
Restructuring and private placement
Furthermore, Mylan will undertake a restructuring to ...